Spanish drugmaker Grifols said on Thursday it expects its revenue, core earnings and free cash flow to grow significantly in ...

Spanish drugmaker Grifols reported on Wednesday a net profit of 157 million euros ($165.02 million) for 2024 on revenues of 7 ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...

Grifols revenue and EBITDA growth, improved leverage ratio, and significant liquidity highlight its resilience and potential ...

Building on the solid performance of 2024, Grifols (GRFS) forecasts continued success in 2025 with anticipated revenue growth and EBITDA ...

Grifols (GRFS) hosted it 2025 Capital Markets Day on February 27 in London, where the company announced it would double revenue to EUR 14 ...

Nearly one million people in the U.S. and more than six million people worldwide have Parkinson's disease (PD), a debilitating neurological condition characterized by progressive motor and non-motor ...

Learn more about whether Alkermes plc or Grifols, S.A. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

"We urge the CNMV to consider the benefits to all Grifols shareholders from improved disclosure," Mason Capital said. As global markets navigate a mixed economic landscape marked by declining ...

Pharmaceutical giants like Eli Lilly and Grifols report significant investment and growth. In the U.S., Eli Lilly plans a $27 billion investment in manufacturing plants, while Grifols reports a 10% ...

Grifols said it expects positive free cash flow to rise to €1.2-billion in 2029 and to €350 million-€400-million in 2025 ...

BARCELONA, Feb 26 (Reuters) - Spanish drugmaker Grifols (GRLS.MC), opens new tab reported on Wednesday a net profit of 157 million euros ($165.02 million) for 2024 on revenues of 7.21 billion ...